Canada Gives Samsung Bioepis A Further Ranibizumab Approval

Health Canada Nod For Byooviz Lucentis Rival Follows US And EU

 
• By Dave Wallace

Samsung Bioepis has racked up a further endorsement for its Byooviz biosimilar ranibizumab, after Health Canada approved the rival to Lucentis.

Canada flag eye
Samsung Bioepis has the first Canadian approval for the ophthalmic biosimilar • Source: Bo Valentino / Alamy Stock Photo

More from Biosimilars

More from Products